|
May 8
|
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
|
|
May 6
|
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
|
|
Apr 29
|
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
|
|
Apr 26
|
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
|
|
Apr 25
|
Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 24
|
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
|
|
Apr 8
|
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
|
|
Apr 3
|
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 20
|
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
|
|
Mar 6
|
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
|
|
Mar 6
|
Gilead bets on ‘trispecifics’ in latest cancer drug deal
|
|
Mar 5
|
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
|
|
Mar 5
|
Merus Full Year 2023 Earnings: Misses Expectations
|
|
Mar 4
|
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
|
|
Jan 10
|
Prothena (PRTA) Surges 12.3%: Is This an Indication of Further Gains?
|
|
Jan 9
|
Merus N.V. (NASDAQ:MRUS) Shares Could Be 44% Below Their Intrinsic Value Estimate
|
|
Jan 9
|
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
|
|
Dec 12
|
Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet
|
|
Dec 5
|
Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade
|
|
Dec 3
|
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
|